Further research is needed to understand the clinical implications of ILAs in COPD and their association with comorbidities.

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD ...

Quantitative CT findings may be useful in identifying early, clinically significant airway disease in patients with rheumatoid arthritis.